New Zealand Living Cell-Otsuka Partnership Implants Pig Cells Into Parkinson’s Patient: AusBiotech
This article was originally published in PharmAsia News
Executive Summary
New Zealand’s Living Cell Technologies has taken a key clinical step in regenerative and replacement branded cell therapy work focused on Parkinson’s disease and type 1 diabetes that has drawn investment from Japan’s Otsuka. The progress report was presented at the Australia Biotech Invest conference in Melbourne in late October.
You may also be interested in...
New Zealand's Living Cell Technologies Closer To Getting Pigs To Market
PERTH, Australia - Auckland-based cell implant company Living Cell Technologies has started working on an animal-derived therapeutics project with the New Zealand government's investment promotion agency, Investment New Zealand
Considering Growth Options For Asian Biotechs: IPO Vs M&A
Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.
Nanjing BioPoint Shoots For 2018 Double POC Launch; Seeks $10m
A China-based IVD company, spun out of an Australian medical research institute, is seeking investors to support its plans for the 2018 launch its first two point-of-care tests for patients with infectious diseases including HIV and viral hepatitis.